Dr Evans, a lecturer in microbiology and medical biotechnology, said: "One of the greatest threats to modern medicine is the increasing prevalence of antibiotic-resistant bacteria, and with Acinetobacter baumannii
we are essentially talking about something that is as at least as dangerous as MRSA and much more difficult to eradicate.
It's multidrug resistant Acinetobacter baumannii
and it was introduced into North America by troops returning from the Middle East in Canadian soldiers injured and requiring mechanical ventilation as a part of the medical treatment.
Background: Acinetobacter baumannii
causes infections of respiratory, urinary tract, blood stream and surgical sites.
is an emerging gram-negative nosocomial pathogen responsible for an increasing number of infections, especially among intensive-care-unit patients.
The emergence of multidrug-resistant Acinetobacter baumannii
in Colombia: A time-series analysis, 2001-2007
The genomic identification of Colombian Acinetobacter baumannii
clinical isolates by RFLP-PCR analysis of the 16S-23S rRNA gene spacer region
multidrug and pandrug resistant: perspective, resistance mechanisms and treatment
All isolates of acinetobacter baumannii
(n=32) were resistant to ampicillin, ceftriaxone and ceftazidime but sensitive to polymyxin B.
has been considered the prevailing pathogen responsible for ventilator-associated pneumonia (VAP), a condition associated with high morbidity and mortality, among patients in Intensive Care Units (ICUs).
was mostly sensitive to amikacin (65%; n = 13/20) and ceftazidime (75%; n = 15/20), with high levels of resistance to gentamicin (85%) and meropenem (80%).
Spread of Multidrug-Resistant Acinetobacter baumannii
Prevalence of multi drug resistant Acinetobacter baumannii
in the clinical samples from Tertiary Care Hospital in Islamabad, Pakistan.